Hepatic lymph node metastases in patients with colorectal liver metastases undergoing hepatic artery infusion pump placement.
[BACKGROUNDS/AIMS] The status of portal lymph nodes is a critical factor in determining eligibility for hepatic artery infusion pump (HAIP) therapy.
- 표본수 (n) 23
- 추적기간 23.5 months
APA
Dinerman AJ, Eade AV, et al. (2026). Hepatic lymph node metastases in patients with colorectal liver metastases undergoing hepatic artery infusion pump placement.. Annals of hepato-biliary-pancreatic surgery, 30(1), 15-23. https://doi.org/10.14701/ahbps.25-158
MLA
Dinerman AJ, et al.. "Hepatic lymph node metastases in patients with colorectal liver metastases undergoing hepatic artery infusion pump placement.." Annals of hepato-biliary-pancreatic surgery, vol. 30, no. 1, 2026, pp. 15-23.
PMID
41330430
Abstract
[BACKGROUNDS/AIMS] The status of portal lymph nodes is a critical factor in determining eligibility for hepatic artery infusion pump (HAIP) therapy. However, methods for detecting occult positive nodes and understanding their clinical implications remain inadequately defined.
[METHODS] We conducted a retrospective evaluation of a cohort of patients with metastatic colorectal cancer who underwent HAIP. An independent, blinded radiologist reviewed pre-operative imaging to identify predictors for nodal positivity. We performed Kaplan-Meier survival analyses to explore the relationship between hepatic nodal staging and patient survival.
[RESULTS] The study comprised 33 patients, with a median follow-up of 23.5 months (range 2-56 months). The imaging review did not accurately identify patients with hepatic nodal disease. Patients without hepatic nodal metastases (n = 23) had a significantly longer median overall survival (OS) of 27 months compared to those with hepatic nodal metastases, who had a median OS of 11 months (hazard ratio = 4.8, ≤ 0.01). Hepatic nodal positivity (hLN+) was associated with primary nodal positivity (pLN+, = 0.036), and all patients with hLN+ were also pLN+.
[CONCLUSIONS] Hepatic nodal metastases are a predictor of survival in patients receiving HAIP therapy for colorectal liver metastases. Primary nodal positivity may aid in the selection of HAIP candidates by increasing the suspicion of hepatic nodal positivity.
[METHODS] We conducted a retrospective evaluation of a cohort of patients with metastatic colorectal cancer who underwent HAIP. An independent, blinded radiologist reviewed pre-operative imaging to identify predictors for nodal positivity. We performed Kaplan-Meier survival analyses to explore the relationship between hepatic nodal staging and patient survival.
[RESULTS] The study comprised 33 patients, with a median follow-up of 23.5 months (range 2-56 months). The imaging review did not accurately identify patients with hepatic nodal disease. Patients without hepatic nodal metastases (n = 23) had a significantly longer median overall survival (OS) of 27 months compared to those with hepatic nodal metastases, who had a median OS of 11 months (hazard ratio = 4.8, ≤ 0.01). Hepatic nodal positivity (hLN+) was associated with primary nodal positivity (pLN+, = 0.036), and all patients with hLN+ were also pLN+.
[CONCLUSIONS] Hepatic nodal metastases are a predictor of survival in patients receiving HAIP therapy for colorectal liver metastases. Primary nodal positivity may aid in the selection of HAIP candidates by increasing the suspicion of hepatic nodal positivity.